Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3804-3814

  Herbst, Roy S ^a   Mullani, Nizar A ^a   Davis, Darren W ^a   Hess, Kenneth R ^a   McConkey, David J ^a   Charnsangavej, Chusilp ^a   O'Reilly, Michael S ^a   Kim, Hyung Woo ^a   Baker, Cheryl ^a   Roach, Jennifer ^a   Ellis, Lee M ^a   Rashid, Asif ^a   Pluda, James ^a   Bucana, Corazon ^a   Madden, Timothy L ^a   Tran, Hai T ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOSTATIN; FLUORINE 18; FLUORODEOXYGLUCOSE; OXYGEN 15; WATER;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ACTIVITY; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; TUMOR BIOPSY; TUMOR BLOOD FLOW; TUMOR CELL; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIGENS, CD3; APOPTOSIS; BIOLOGICAL MARKERS; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSTATINS; ENDOTHELIUM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IN SITU NICK-END LABELING; LASERS; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037106384     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.05.102     Document Type: Article

References (41)

1. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
2. Tumor angiogenesis: Therapeutic implications
3. Angiogenesis in cancer, vascular, rheumatoid and other disease
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
6. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
7. Endostatin induces endothelial cell apoptosis
8. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis
9. Antiangiogenesis signals by endostatin
10. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
11. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay
12. Endostatin binds tropomyosin: A potential modulator of the antitumor activity of endostatin
13. Interaction of endostatin with integrins implicated in angiogenesis
14. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
15. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells
16. Phase I study of recombinant human endostatin in patients with advanced solid tumors
17. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia
18. Simple and Patlak models for myocardial blood flow measurements with nitrogen-13-ammonia and PET in humans
19. Sensitivity of measurements of regional brain activation with oxygen-15-water and PET to time of stimulation and period of image reconstruction
20. Anatomy of SUV: Standardized uptake value
21. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
22. Robust locally weighted regression and smoothing scatterplots
23. The proof and measurement of association between two things: By C. Spearman, 1904
24. Fitting piecewise linear regression functions to biological responses
25. Angiostatin induces and sustains dormancy of human primary tumors in mice
26. Cell surface glypicans are low-affinity endostatin receptors
27. Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile
28. Measuring tumor blood flow with H(2)(15)O: Practical considerations
29. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilization, and blood volume in patients with breast carcinoma
30. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method
31. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas
32. Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state tehnique: Effect of tissue heterogeneity
33. Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 150 and positron emission tomography: Analytical techniques and preliminary results
34. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
35. Barriers to drug delivery in solid tumors
36. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
37. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
38. Cloning, expression, and in vitro activity of human endostatin
39. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
40. Molecular addresses in blood vessels as targets for therapy
41. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications